Literature DB >> 5559480

Methods for the production of clinically effective intermediate- and high-purity factor-VIII concentrates.

J Newman, A J Johnson, M H Karpatkin, S Puszkin.   

Abstract

Mesh：

Substances：

Year:  1971        PMID： 5559480     DOI： 10.1111/j.1365-2141.1971.tb03413.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  23 in total

1.  Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure.

Authors:  M E Switzer; P A McKee
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

2.  An alternative method of large scale plasma fractionation for the isolation of serum albumin.

Authors:  W Schneider; H Lefévre; H Fiedler; L J McCarty
Journal:  Blut       Date:  1975-02

3.  Report of a clinical trial of a Canadian preparation of antihemophilic factor.

Authors:  A A Magnin; S E Johnson
Journal:  Can Med Assoc J       Date:  1979-08-18       Impact factor: 8.262

4.  Studies on the procurement of blood coagulation factor VIII: effects of plasma freezing rate and storage conditions on cryoprecipitate quality.

Authors:  A Farrugia; C Prowse
Journal:  J Clin Pathol       Date:  1985-04       Impact factor: 3.411

5.  An endothelial cell-dependent pathway of coagulation.

Authors:  D Stern; P Nawroth; D Handley; W Kisiel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

6.  A coagulation pathway on bovine aortic segments leading to generation of Factor Xa and thrombin.

Authors:  D M Stern; P P Nawroth; W Kisiel; D Handley; M Drillings; J Bartos
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

7.  The subunit structure of normal and hemophilic factor VIII.

Authors:  G A Shapiro; J C Andersen; S V Pizzo; P A McKee
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

8.  Haemophilia A and the blood transfusion service: a Scottish study.

Authors:  J D Cash; M Spencely
Journal:  Br Med J       Date:  1976-09-18

9.  Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation.

Authors:  A B Federici; J H Elder; L De Marco; Z M Ruggeri; T S Zimmerman
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

10.  von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease.

Authors:  J L Miller; J M Kupinski; A Castella; Z M Ruggeri
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.